 | • レポートコード：MRC2203A089 • 出版社/出版日：Mordor Intelligence / 2022年1月 • レポート形態：英文、PDF、115ページ • 納品方法：Eメール（受注後2-3営業日） • 産業分類：医療 |
| Single User | ￥703,000 (USD4,750) | ▷ お問い合わせ |
| Site Licence | ￥962,000 (USD6,500) | ▷ お問い合わせ |
| Corporate License | ￥1,295,000 (USD8,750) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| Mordor Intelligence社の本市場調査レポートでは、世界の犬アトピー性皮膚炎市場について調査・分析し、イントロダクション、調査手法、エグゼクティブサマリー、市場動向、治療種類別（糖質コルチコイド、免疫抑制剤、モノクローナル抗体、その他）分析、投与経路別（局所、経口、注射）分析、地域別（北米、ヨーロッパ、アジア太平洋、中東・アフリカ、南米）分析、競争状況、市場機会・将来傾向など、以下の構成でまとめました。 ・イントロダクション ・調査手法 ・エグゼクティブサマリー ・市場動向 ・世界の犬アトピー性皮膚炎市場規模：治療種類別（糖質コルチコイド、免疫抑制剤、モノクローナル抗体、その他） ・世界の犬アトピー性皮膚炎市場規模：投与経路別（局所、経口、注射） ・世界の犬アトピー性皮膚炎市場規模：地域別（北米、ヨーロッパ、アジア太平洋、中東・アフリカ、南米） ・競争状況（Zoetis、Elanco、Virbac、…） ・市場機会・将来傾向 |
The canine atopic dermatitis market was valued at approximately USD 683.63 million in 2020. It is expected to witness a revenue of USD 1,107.86 million in 2026, with a CAGR of 8.46% over the forecast period (2021-2026).
The impact of COVID-19 on the canine atopic dermatitis market is expected to be significant. As per the data of the Centers for Disease Control and Prevention, cats, dogs, and a few other types of animals are at potential risk of acquiring this virus. Several studies are still ongoing concerning the connection between animals and human transmission of this virus. However, governments have been taking measures to mitigate the supply of medicines. For instance, the European Medicines Agency issued guidance for companies responsible for veterinary medicines, regarding the adaptations to the regulatory framework, primarily to address the challenges faced during the pandemic. IN July 2020, the Centers for Disease Control and Prevention recommended certain guidelines to the veterinary professionals for the treatment of companion animals during the COVID-19 pandemic. Additionally, as per the research article published in Humanities and Social Sciences Communications, 2020, the total number of online searches on the Yad4 website was 221,959 in April 2020 compared to 72,703 in April 2019. The study revealed the growing rate of dog adoption during the pandemic. Therefore, owing to such factors, the canine atopic dermatitis market is expected to be impacted during the pandemic.
Environmental factors are responsible for many allergies and diseases, which is expected to drive market growth. Increasing R&D activities are also expected to drive the market. For instance, in January 2020, Boragen partnered with one of the global leading animal health companies, exclusively for the R&D activity related to the development of new treatment of canine atopic dermatitis. Also, as per the research article published in Veterinary Medicine and Science, 2020, Luteolin was evaluated to study the antioxidant effect in the treatment of canine atopic dermatitis. The results revealed that Luteolin was able to drastically minimize the levels of IL‐33, IL 1β, IL‐6, and IL‐8 and suggested that Luteolin is a promising agent in pharmacological treatment for canine atopic dermatitis. Hence, such factors are expected to boost the canine atopic dermatitis market during the forecast period.
Key Market Trends
The Monoclonal Antibody Segment is Expected to Exhibit Significant Market Growth Over the Forecast Period
The monoclonal antibodies segment is expected to exhibit a thriving market growth over the forecast period. The major attributable factors are the rising awareness of biotherapeutics and the increasing product approvals.
Lokivetmab is a caninized anti–interleukin-31 (IL-31) mAb developed and licensed by Zoetis. It works by neutralizing soluble IL-31 released primarily by lymphocytes. Lokivetmab is effective against atopic dermatitis and allergic dermatitis in dogs. Furthermore, in 2019, Kindred Biosciences developed a monoclonal antibody, Interleukin-31, for the treatment of canine atopic dermatitis. It completed its pilot study and showed a significant outcome. Hence, advancements in products are expected to positively influence the market.
As per the research article published in the Asian Journal of Epidemiology, 2020, the development of monoclonal antibodies is expected to show similar growth in veterinary medicine that aids in providing promising alternative strategies to overcome the obstacles of drug resistance, adverse effects of drugs, drug residue, and other complications associated with the traditional veterinary drugs. Thus, owing to the aforementioned factors, therapeutic monoclonal antibodies are gaining importance in the treatment of allergic conditions in dogs, which may boost market growth over the forecast period.
North America is Expected to Hold a Significant Share in the Market During the Forecast Period
North America is expected to be a dominant region for the canine atopic dermatitis market, owing to increased spending in R&D activities and the high concentration of key players in the market, along with the high rate of households with dog ownership in the region. According to the Animal Health Institute, the US animal health industry serves around 640 million food animals and 383 million companion animals.
As per the Canadian Animal Health Institute (CAHI), in 2018, there were nearly 8.2 million dogs in Canada. Over a decade, dog ownership has increased significantly in the country. As per the American Pet Products Association, nearly 63.4 million households in the United States owned a dog in 2020. Additionally, dogs occupy 63.4% of the pet share in the United States and owners spend an average of around USD 1,380 on pet dogs’ basic expenses. Thus, high dog ownership in the region is expected to drive market growth.
Also, the new product approvals and strategic alliances by key players are expected to boost the studied market. For instance, in October 2020, Elanco signed an agreement to acquire Bayer’s Animal Health business in a transaction valued at USD 7.6 billion. Thus, owing to the aforementioned factors, the North American canine atopic dermatitis market is expected to register significant growth over the forecast period.
Competitive Landscape
The canine atopic dermatitis market is moderately competitive in nature, with few players dominating the market. Some of the key players that are expected to dominate the canine atopic dermatitis market are Zoetis, Elanco, Virbac, Toray Industries Inc., Dechra Veterinary Products, Kindred Biosciences Inc., and Ceva. The companies adopt various strategies, such as mergers and acquisitions, partnerships, and collaborations, along with the new product launches and research activities, to explore their positions in the market.
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
1 INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Pollution Related to Allergens
4.2.2 Increasing dog ownership
4.3 Market Restraints
4.3.1 Usage of Off-label Drugs
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Treatment Type
5.1.1 Glucocorticoids
5.1.2 Immuno-suppressants
5.1.3 Monoclonal Antibody
5.1.4 Other Treatment Types
5.2 By Route of Administration
5.2.1 Topical
5.2.2 Oral
5.2.3 Injectable
5.3 Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle East and Africa
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle East and Africa
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Zoetis
6.1.2 Elanco
6.1.3 Virbac
6.1.4 Toray Industries Inc.
6.1.5 Kindred Biosciences Inc.
6.1.6 Ceva
6.1.7 Nextmune
6.1.8 Dechra Veterinary Products
6.1.9 Vetoquinol UK Ltd
6.1.10 Bioceltix
6.1.11 Phibro Animal Health Corporation
6.1.12 Bioiberica S.A.U.
6.1.13 Bimeda, Inc.
7 MARKET OPPORTUNITIES AND FUTURE TRENDS